lifestyle.floredechampagne.com

Author: SOLIGENIX, INC.

Soligenix Details Recent Progress and Upcoming Milestones

February 20, 2026
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)

December 18, 2025
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

December 17, 2025